Holen Sie sich die Stockscreener-App
138.99
2.18%
-3.10
Handel nachbörslich:
141.21
2.22
+1.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$142.09
Offen:
$142.38
24-Stunden-Volumen:
4.28M
Relative Volume:
0.61
Marktkapitalisierung:
$172.51B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
20.49
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-0.52%
1M Leistung:
-6.44%
6M Leistung:
+18.61%
1J Leistung:
+37.07%
1-Tages-Spanne:
$138.45
$142.38
1-Wochen-Bereich:
$137.15
$142.97
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
138.99 | 172.51B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration - Yahoo Finance
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake - National Today
Greenup Street Wealth Management Boosts Gilead Sciences Stake - National Today
Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Firm Boosts Gilead Sciences Holdings - National Today
Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area - CSRwire
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy? - simplywall.st
Ritholtz Wealth Management Boosts Gilead Sciences Stake - National Today
Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Taxation With Representation: Goodwin, CMS, Wilson Sonsini - Law360
AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - MarketBeat
Gilead projects $107M Q1 earnings headwind due to recent R&D deals - MSN
Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00 - MarketBeat
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
Tempus AI stock rises on Gilead collaboration deal - Investing.com
Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Tempus AI stock rises on Gilead collaboration deal By Investing.com - Investing.com South Africa
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders - Yahoo Finance
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Why Is Tempus AI Stock Gaining Friday?Tempus AI (NASDAQ:TEM) - Benzinga
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline - Yahoo Finance
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Tempus AI expands collaboration with Gilead Sciences By Investing.com - Investing.com Australia
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Benzinga
Gilead Expands Oncology Pipeline With $5B Tubulis Deal - Yahoo Finance
Focus on HIV therapies propels Gilead Sciences stock consolidation amid mixed technical momentum - Traders Union
Gilead Sciences Sees Institutional Investment Boost - National Today
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead price target raised to $155 from $152 at Truist - Yahoo Finance
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Yahoo Finance
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise - Business Wire
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
MH & Associates Securities Management Corp ADV Invests $4.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
8,451 Shares in Gilead Sciences, Inc. $GILD Bought by Jackson Square Capital LLC - MarketBeat
Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - AOL.com
Germany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bn - Investors in Healthcare
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Gilead to pay up to $5bn for antibody-drug conjugates push - Life Sciences Intellectual Property Review
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts - Yahoo Finance
Gilead's Commitment to Bridging the Unmet HIV Treatment Gap - Gilead Sciences
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):